search
Back to results

The Prevent Anal Cancer Self-Swab Study

Primary Purpose

Anal Cancer

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Home-based human papillomavirus (HPV) DNA screening
Clinic-based human papillomavirus (HPV) DNA screening
Sponsored by
Medical College of Wisconsin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Anal Cancer focused on measuring anal cancer, human papillomavirus

Eligibility Criteria

25 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Be > 25 years of age
  • Sex at birth is male or gender identity is a transgender person
  • Acknowledge sex with men in the last 5 years, or identify as gay or bisexual
  • Understand and be willing to give informed consent
  • Be willing to be randomized and able to comply with the protocol
  • Spanish and/or English speakers/readers, and
  • HIV+ or HIV-

Exclusion Criteria:

  • Not acknowledge sex with men in the past five years and not identify as gay or bisexual
  • Use of anticoagulants other than Aspirin or NSAIDS
  • Prior diagnosis of anal cancer
  • Plans to move within 12 months
  • Not Milwaukee metro residents
  • Not willing to attend one of the designated study clinics at baseline, or
  • Inability to give informed consent

Sites / Locations

  • Medical College of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Home-based human papillomavirus (HPV) DNA screening

Clinic-based human papillomavirus (HPV) DNA screening

Arm Description

Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.

Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.

Outcomes

Primary Outcome Measures

Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening

Secondary Outcome Measures

Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire (pre-test)
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire (pre-test)
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Factors associated with HRA compliance as assessed by the Computer-Assisted Self-Interview (CASI)
Number of participants who agree to have a high resolution anoscopy (HRA)
Number of participants who agree to have a high resolution anoscopy (HRA)

Full Information

First Posted
March 29, 2018
Last Updated
October 14, 2022
Sponsor
Medical College of Wisconsin
Collaborators
National Cancer Institute (NCI), The University of Texas Health Science Center, Houston, M.D. Anderson Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03489707
Brief Title
The Prevent Anal Cancer Self-Swab Study
Official Title
Annual Anal Sampling Using DNA Screening to Identify Men Who Have Sex With Men at Increased Risk for Anal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 9, 2020 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical College of Wisconsin
Collaborators
National Cancer Institute (NCI), The University of Texas Health Science Center, Houston, M.D. Anderson Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this research study is to find ways to screen for anal cancer among gay, bisexual, and other men who have sex with men (MSM) and transgender persons. This study will try to find out if persons will do annual anal cancer screening, what factors are associated with repeated screening, and how this affects a person's decision to have high-resolution anoscopy.
Detailed Description
This is a prospective, randomized, two-arm clinical study to evaluate compliance with annual home-based vs clinic-based DNA screening of anal canal exfoliated cells among Milwaukee HIV+ and HIV- men who have sex with men and transpersons aged ≥25 years. At study entry, persons randomized to arm 1 will receive a home-based collection kit in the mail at 0 and 12 months and those in arm 2 will attend a clinic where a clinician will collect the exfoliated cell specimen at 0 and 12 months. Then, persons will receive HRA-directed biopsy to assess precancerous lesions by study arm. We hypothesize that a majority of persons will comply with annual screening with increased compliance among persons in the home-based arm vs clinic-based arm. The proposed research could indicate that annual HPV DNA screening and subsequent HRA are acceptable to MSM and transpersons; thus, we will determine how high-risk persons are identified for HRA in light of limited HRA resources. The duration of each participant's activities is expected to be 12 months. The study is expected have participant activity from 2019 to 2023.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anal Cancer
Keywords
anal cancer, human papillomavirus

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
253 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Home-based human papillomavirus (HPV) DNA screening
Arm Type
Experimental
Arm Description
Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
Arm Title
Clinic-based human papillomavirus (HPV) DNA screening
Arm Type
Active Comparator
Arm Description
Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
Intervention Type
Behavioral
Intervention Name(s)
Home-based human papillomavirus (HPV) DNA screening
Intervention Description
Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
Intervention Type
Behavioral
Intervention Name(s)
Clinic-based human papillomavirus (HPV) DNA screening
Intervention Description
Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
Primary Outcome Measure Information:
Title
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Description
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Time Frame
baseline
Title
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Description
Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire (pre-test)
Description
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire (pre-test)
Time Frame
about a week before the first DNA screening
Title
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Description
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Time Frame
about 1 hour after the first DNA screening
Title
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Description
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Time Frame
about 1 hour after the 12 month DNA screening
Title
Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
Description
Factors associated with HRA compliance as assessed by the Computer-Assisted Self-Interview (CASI)
Time Frame
about 1 hour after the HRA (HRA occurs about 2 weeks after the 12-month DNA screening)
Title
Number of participants who agree to have a high resolution anoscopy (HRA)
Description
Number of participants who agree to have a high resolution anoscopy (HRA)
Time Frame
2 weeks after the 12-month DNA screening
Other Pre-specified Outcome Measures:
Title
Human papillomavirus (HPV) DNA persistence and its association with high-grade squamous intraepithelial lesions.
Description
Human papillomavirus (HPV) DNA persistence and its association with high-grade squamous intraepithelial lesions: The presence of high-risk HPV (human papillomavirus) DNA will be assessed at baseline and at 12 months. High-risk HPV types that are present at both time points determines the presence of persistence of high-risk HPV DNA. HPV DNA persistence will be assessed for its association with high-grade squamous intraepithelial lesions.
Time Frame
12 months
Title
Host/viral methylation and its association with high-grade squamous intraepithelial lesions.
Description
Host/viral methylation and its association with high-grade squamous intraepithelial lesions: The presence of host/viral methylation patterns will be assessed at baseline and at 12 months. Methylation patterns that are present at either time point will be assessed for its association with high-grade squamous intraepithelial lesions.
Time Frame
12 months

10. Eligibility

Sex
All
Gender Based
Yes
Gender Eligibility Description
cis males and transgender persons who have sex with men
Minimum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Be > 25 years of age Sex at birth is male or gender identity is a transgender person Acknowledge sex with men in the last 5 years, or identify as gay or bisexual Understand and be willing to give informed consent Be willing to be randomized and able to comply with the protocol Spanish and/or English speakers/readers, and HIV+ or HIV- Exclusion Criteria: Not acknowledge sex with men in the past five years and not identify as gay or bisexual Use of anticoagulants other than Aspirin or NSAIDS Prior diagnosis of anal cancer Plans to move within 12 months Not Milwaukee metro residents Not willing to attend one of the designated study clinics at baseline, or Inability to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alan G Nyitray, PhD
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53202
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Fully de-identified datasets will be shared with properly trained investigators after assessment of institutional policies, Medical College of Wisconsin Human Protections Committee rules, as well as local, state, and Federal laws and regulations.
IPD Sharing Time Frame
Data will become available three years after study completion and be available for five years.
IPD Sharing Access Criteria
Fully de-identified datasets will be shared with properly trained investigators after assessment of institutional policies, Medical College of Wisconsin Human Protections Committee rules, as well as local, state, and Federal laws and regulations.
Citations:
PubMed Identifier
34187833
Citation
Nyitray AG, Schick V, Swartz MD, Giuliano AR, Fernandez ME, Deshmukh AA, Ridolfi TJ, Ajala C, Brzezinski B, Sandoval M, Nedjai B, Smith JS, Chiao EY. Rationale and design of the Prevent Anal Cancer Self-Swab Study: a protocol for a randomised clinical trial of home-based self-collection of cells for anal cancer screening. BMJ Open. 2021 Jun 29;11(6):e051118. doi: 10.1136/bmjopen-2021-051118.
Results Reference
derived

Learn more about this trial

The Prevent Anal Cancer Self-Swab Study

We'll reach out to this number within 24 hrs